1. Home
  2. ZS vs WAT Comparison

ZS vs WAT Comparison

Compare ZS & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zscaler Inc.

ZS

Zscaler Inc.

HOLD

Current Price

$227.65

Market Cap

52.0B

Sector

Technology

ML Signal

HOLD

Logo Waters Corporation

WAT

Waters Corporation

HOLD

Current Price

$382.97

Market Cap

22.5B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZS
WAT
Founded
2007
1958
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Laboratory Analytical Instruments
Sector
Technology
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
52.0B
22.5B
IPO Year
2018
1995

Fundamental Metrics

Financial Performance
Metric
ZS
WAT
Price
$227.65
$382.97
Analyst Decision
Buy
Buy
Analyst Count
34
15
Target Price
$323.73
$390.67
AVG Volume (30 Days)
1.8M
547.4K
Earning Date
11-25-2025
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.82
EPS
N/A
10.88
Revenue
$2,833,272,000.00
$3,105,638,000.00
Revenue This Year
$27.01
$7.96
Revenue Next Year
$19.32
$6.32
P/E Ratio
N/A
$35.41
Revenue Growth
23.24
6.90
52 Week Low
$164.78
$275.05
52 Week High
$336.99
$423.56

Technical Indicators

Market Signals
Indicator
ZS
WAT
Relative Strength Index (RSI) 29.60 49.94
Support Level $226.78 $372.17
Resistance Level $231.06 $389.16
Average True Range (ATR) 5.14 7.63
MACD 1.79 -1.24
Stochastic Oscillator 7.47 42.55

Price Performance

Historical Comparison
ZS
WAT

About ZS Zscaler Inc.

Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.

About WAT Waters Corporation

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.

Share on Social Networks: